Tocqueville Asset Management’s Acurx Pharmaceuticals ACXP Stock Holding History

Tocqueville Asset Management’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$19K	–	539
2024 Q3	$19K	Hold	500	–	–	﹤0.01%	526
2024 Q2	$22.5K	Hold	500	–	–	﹤0.01%	525
2024 Q1	$24.5K	Sell	500 -155	-24%	-$10.1K	﹤0.01%	534
2023 Q4	$50.2K	Buy	655 +150	+30%	+$11.3K	﹤0.01%	512
2023 Q3	$15.2K	Hold	505	–	–	﹤0.01%	512
2023 Q2	$26.8K	Hold	505	–	–	﹤0.01%	532
2023 Q1	$34.9K	Hold	505	–	–	﹤0.01%	525
2022 Q4	$40.2K	Hold	505	–	–	﹤0.01%	570
2022 Q3	$30K	Hold	505	–	–	﹤0.01%	591
2022 Q2	$38K	Hold	505	–	–	﹤0.01%	657
2022 Q1	$33K	Sell	505 -750	-60%	-$58.8K	﹤0.01%	702
2021 Q4	$108K	Buy	1,255 +300	+31%	+$28.5K	﹤0.01%	726
2021 Q3	$98K	Buy	955 +455	+91%	+$47K	﹤0.01%	719
2021 Q2	$64K	Buy	+500	New	+$66.9K	﹤0.01%	732

Other funds holding ACXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

Tocqueville Asset Management's ACXP Position: Q4 2024 in Review

Tocqueville Asset Management sold out of Acurx Pharmaceuticals (ACXP) in Q4 2024, closing a stake of 500 shares — an estimated $19K sold.

Tocqueville Asset Management first reported a position in ACXP in Q2 2021 and held it in 14 quarters. The position peaked at $108K in Q4 2021. 26 funds tracked by Wall St. Rank hold ACXP as of Q4 2024.

Tocqueville Asset Management reported no remaining Acurx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Tocqueville Asset Management sold 500 Acurx Pharmaceuticals shares in Q4 2024, an estimated $19K.
Tocqueville Asset Management first reported a position in Acurx Pharmaceuticals in Q2 2021 and held it in 14 quarters.
Tocqueville Asset Management's Acurx Pharmaceuticals position peaked at $108K in Q4 2021.
26 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2024.

Based on Tocqueville Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.